| Atara Biotherapeutics is an off-the-shelf, allogeneic T-cell immunotherapy company that is developing treatments for patients with cancer, autoimmune and viral diseases. Co.'s primary T-cell immunotherapy, tab-cel® (tabelecleucel), is in development for patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disease who have failed rituximab or rituximab plus chemotherapy, and other EBV-associated hematologic malignancies and solid tumors. Co.'s T-cell immunotherapies in clinical development include ATA188: T-cell immunotherapies targeting EBV antigens for the treatment of multiple sclerosis; and ATA2271/ATA3271: CAR T immunotherapy targeting mesothelin. We show 24 historical shares outstanding datapoints in our ATRA shares outstanding history coverage, used to compute ATRA market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ATRA market cap history over the course of time is important for investors
interested in comparing ATRA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ATRA versus a peer is one thing; comparing
ATRA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ATRA can fluctuate over the course of history.
With this page we aim to empower investors researching ATRA by allowing them to research the ATRA market cap history.